Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.
S DicuonzoM C LeonardiS RaimondiGiulia CorraoV BagnardiM A GerardiA MorraM A ZerellaM ZaffaroniF PansiniF CattaniR LuraschiC FodorP VeronesiR OrecchiaD P RojasB A Jereczek-FossaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Hypofractionated WB IMRT with a SIB to the TB, delivered with TomoDirect modality, is safe and well-tolerated. Most patients reported no toxicity after 6 months and good-excellent cosmesis. Predictive factors of clinically relevant toxicity might be considered during treatment planning in order to further reduce side effects.
Keyphrases
- end stage renal disease
- oxidative stress
- radiation therapy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early stage
- liver failure
- prognostic factors
- mycobacterium tuberculosis
- oxide nanoparticles
- randomized controlled trial
- patient reported outcomes
- drug induced
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- placebo controlled